Monthly Archives: July 2010

IMS Health data for 2009 creates an interesting picture of global drug sales and growth in specific therapeutic classes. WBC (wbcbaltimore.com) has taken a look and found that the global picture is clearly different when compared to  U.S. pharmacy benefit plan sponsor drug spend.  In the U.S., antipsychotics were the leading therapeutic class with $14.6 billion in sales. […]

Decisions decisions! Benefit managers and prescription benefit plan sponsors face the challenging balancing act of getting more members to take their medications while controlling their health plan costs. The logic appears intuitive: the more members stay compliant with their drug regimens, the fewer emergency room visits and in-patient hospitalizations.  Studies have shown that 25% of prescriptions go […]